Company
NASDAQ:POAI
Predictive Oncology Inc is a knowledge-driven company focused on applying artificial intelligence (AI) to the research and development process of personalized cancer therapies, which can lead to better treatments, improved patient outcomes and faster time to market. By utilizing its flagship AI-powered drug discovery platform, Predictive Oncology can analyze well-characterized patient tumor databases from multiple cancer types against a variety of drug compounds. The company's AI engine takes a multiomic approach, which considers the vast multitude of factors that make each cancer unique, in the prediction of responders and non-responders by tumor and drug type. The output provides a set of tumor types and drug compounds that are more likely to succeed in clinical development and ultimately succeed in optimal therapy selection for patients.
34 stories · page 2 of 2
“He is an experienced biotechnology executive who brings an informed vision and fresh perspective to our company as we strive to become a significant player in the pharmaceutical and biotech industries,” Predictive Oncology chief financial
Predictive Oncology CEO J Melville Engle said adding GMP production capabilities was a major accomplishment that had been underway over the past year and a half
The Minnesota-based company recognized net sales revenue of $400,000 for the three months ended June 30, 2022, an increase of 6% from the year-ago period, mainly due to a $100,000 sales contribution from its zPREDICTA subsidiary
Dr Kirshner will oversee the scientific process for the entire suite of solutions POAI offers for oncology drug development, ranging from early discovery to clinical trials
The company intends to use the net proceeds from the offerings for working capital purposes
Net proceeds are expected to be used for working capital purposes
"We are extremely excited that our technology provides a significant competitive advantage to our business offerings,” J. Melville Engle, the company's chairman and chief executive officer said
The company is set to be a first mover in the artificial intelligence powered drug discovery market that will grow to $20 billion in the next three years
Ferguson steps in as the company begins commercialization of its knowledge-driven technologies, applying artificial intelligence (AI) to develop personalized cancer therapies and improve patient outcomes
"M&A activity in 2021 was highlighted by the acquisition of zPREDICTA Inc, whose established business model and integration of organ-specific cellular and extracellular elements into 3D culture models for in-vitro cancer drug testing is bel
The company, which is focused on applying artificial intelligence to develop personalized cancer therapies said the results from Discovery 21 are now validated and PeDAL “accurately and reproducibly” predicted drug response results
Predicative Oncology expects to sign new partners this year and establish a new revenue stream from PeDAL-powered projects
Analysts at HC Wainwright noted that the company’s artificial intelligence platform has demonstrated “promising predictive capability”
